Ser203
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser203  -  PGK1 (human)

Site Information
yFAkALEsPERPFLA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 468410

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 1 ) , immunoprecipitation ( 5 ) , mass spectrometry ( 2 , 3 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 20 , 21 , 22 , 23 , 24 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 ) , mutation of modification site ( 5 ) , phospho-antibody ( 1 , 5 ) , phosphoamino acid analysis ( 5 ) , western blotting ( 1 , 5 )
Disease tissue studied:
Alzheimer's disease ( 52 ) , brain cancer ( 5 ) , glioblastoma ( 5 ) , glioma ( 5 ) , breast cancer ( 6 , 12 , 13 , 22 , 23 ) , breast ductal carcinoma ( 12 ) , HER2 positive breast cancer ( 3 ) , luminal A breast cancer ( 3 ) , luminal B breast cancer ( 3 ) , breast cancer, surrounding tissue ( 3 ) , breast cancer, triple negative ( 3 , 12 ) , cervical cancer ( 43 ) , cervical adenocarcinoma ( 43 ) , leukemia ( 27 , 29 , 54 , 55 ) , acute myelogenous leukemia ( 27 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 21 ) , acute megakaryoblastic leukemia (M7) ( 21 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 21 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 21 ) , acute myeloblastic leukemia, without maturation (M1) ( 21 ) , chronic myelogenous leukemia ( 54 , 55 ) , T cell leukemia ( 29 ) , hepatocellular carcinoma, surrounding tissue ( 41 ) , lung cancer ( 10 , 23 , 34 , 50 ) , non-small cell lung cancer ( 23 , 50 ) , non-small cell lung adenocarcinoma ( 10 ) , lymphoma ( 14 ) , B cell lymphoma ( 21 ) , Burkitt's lymphoma ( 14 ) , non-Hodgkin's lymphoma ( 21 ) , follicular lymphoma ( 14 ) , mantle cell lymphoma ( 14 ) , ovarian cancer ( 12 ) , multiple myeloma ( 21 , 40 ) , melanoma skin cancer ( 9 ) , cancer, squamous cell carcinoma ( 1 ) , FTLD ( 33 )
Relevant cell line - cell type - tissue:
'brain, cerebral cortex' ( 33 , 52 ) , 'muscle, skeletal' ( 28 , 45 ) , 1363-EBV (lymphoblastoid) ( 46 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 38 ) , 786-O (renal) [VHL (human), transfection] ( 7 ) , 786-O (renal) ( 7 ) , A498 (renal) ( 39 ) , A549 (pulmonary) ( 17 ) , AML-193 (monocyte) ( 21 ) , B lymphocyte-blood ( 40 ) , BJAB (B lymphocyte) ( 14 ) , breast ( 1 , 3 , 12 ) , BT-20 (breast cell) ( 23 ) , BT-474 (breast cell) ( 6 ) , BT-549 (breast cell) ( 23 ) , Calu 6 (pulmonary) ( 23 ) , CL1-0 (pulmonary) ( 34 ) , CL1-1 (pulmonary) ( 34 ) , CL1-2 (pulmonary) ( 34 ) , CL1-5 (pulmonary) ( 34 ) , CMK (megakaryoblast) ( 21 ) , CTS (myeloid) ( 21 ) , DG75 (B lymphocyte) ( 36 ) , DOHH2 ('B lymphocyte, precursor') ( 21 ) , esophagus ( 1 ) , FL-18 (B lymphocyte) ( 14 ) , FL-318 (B lymphocyte) ( 14 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 24 ) , Flp-In T-Rex-293 (epithelial) ( 24 ) , H2009 (pulmonary) ( 23 ) , H2077 (pulmonary) ( 23 ) , H2887 (pulmonary) ( 23 ) , H322M (pulmonary) ( 23 ) , HCC1359 (pulmonary) ( 23 ) , HCC1937 (breast cell) ( 23 ) , HCC2279 (pulmonary) ( 23 ) , HCC366 (pulmonary) ( 23 ) , HCC4006 (pulmonary) ( 23 ) , HCC78 (pulmonary) ( 23 ) , HCC827 (pulmonary) ( 23 ) , HEK293T (epithelial) ( 8 ) , HEL (erythroid) ( 21 ) , HeLa (cervical) ( 2 , 11 , 20 , 30 , 32 , 35 , 44 , 51 , 56 , 59 , 60 ) , HeLa S3 (cervical) ( 43 ) , hepatocyte-liver ( 41 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 13 ) , HMLER ('stem, breast cancer') ( 13 ) , HOP62 (pulmonary) ( 23 ) , HUES-9 ('stem, embryonic') ( 31 ) , JEKO-1 (B lymphocyte) ( 14 ) , Jurkat (T lymphocyte) ( 18 , 37 , 49 , 57 , 58 ) , K562 (erythroid) ( 20 , 44 , 53 , 54 , 55 ) , Kasumi-1 (myeloid) ( 21 ) , KG-1 (myeloid) ( 21 , 27 ) , Kit225 (T lymphocyte) ( 29 ) , LCLC-103H (pulmonary) ( 23 ) , leukocyte-blood ( 42 ) , liver ( 1 , 16 ) , LOU-NH91 (squamous) ( 23 ) , lung ( 1 ) , MCF-7 (breast cell) ( 6 , 23 ) , MDA-MB-231 (breast cell) ( 23 ) , MDA-MB-468 (breast cell) ( 23 ) , MV4-11 (macrophage) ( 21 ) , NCEB-1 (B lymphocyte) ( 14 ) , NCI-H1299 (pulmonary) ( 50 ) , NCI-H1395 (pulmonary) ( 23 ) , NCI-H1568 (pulmonary) ( 23 ) , NCI-H157 (pulmonary) ( 23 ) , NCI-H1648 (pulmonary) ( 23 ) , NCI-H1666 (pulmonary) ( 23 ) , NCI-H2030 (pulmonary) ( 23 ) , NCI-H2172 (pulmonary) ( 23 ) , NCI-H322 (pulmonary) ( 23 ) , NCI-H460 (pulmonary) ( 23 , 47 ) , NCI-H520 (squamous) ( 23 ) , NCI-H647 (pulmonary) ( 23 ) , OCI-ly1 (B lymphocyte) ( 14 ) , OPM-2 (plasma cell) ( 21 ) , ovary ( 12 ) , P31/FUJ (erythroid) ( 21 ) , PC9 (pulmonary) ( 10 , 23 ) , Raji (B lymphocyte) ( 14 ) , RAMOS (B lymphocyte) ( 14 ) , REC-1 (B lymphocyte) ( 14 ) , RL ('B lymphocyte, precursor') ( 21 ) , RPMI-8266 (plasma cell) ( 21 ) , SH-SY5Y (neural crest) [LRRK2 (human), transfection, over-expression of LRRK2(G2019S)] ( 15 ) , SH-SY5Y (neural crest) ( 15 ) , SKBr3 (breast cell) ( 22 ) , stomach ( 1 ) , SU-DHL-4 (B lymphocyte) ( 14 ) , SU-DHL-6 (B lymphocyte) ( 21 ) , U266 (plasma cell) ( 21 ) , U87MG (glial) ( 5 ) , UPN-1 (B lymphocyte) ( 14 ) , WM115 (melanocyte) ( 48 ) , WM239A (melanocyte) ( 9 )

Upstream Regulation
Kinases, in vitro:
ERK2 (human) ( 5 )
Treatments:
hypoxia ( 5 ) , U0126 ( 5 )

Downstream Regulation
Effects of modification on PGK1:
intracellular localization ( 5 ) , protein conformation ( 5 )
Effects of modification on biological processes:
carcinogenesis, induced ( 1 )

Disease / Diagnostics Relevance
Relevant diseases:
breast cancer ( 1 ) , esophageal carcinoma ( 1 ) , gastric cancer ( 1 ) , hepatocellular carcinoma ( 1 ) , lung cancer ( 1 )

References 

1

Shao F, et al. (2019) Associations of PGK1 promoter hypomethylation and PGK1-mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA pan-cancer analysis. Cancer Commun (Lond) 39, 54
31578148   Curated Info

2

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

3

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

4

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

5

Li X, et al. (2016) Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis. Mol Cell 61, 705-19
26942675   Curated Info

6

Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290
27362937   Curated Info

7

Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72
26506913   Curated Info

8

Franchin C, et al. (2015) Quantitative analysis of a phosphoproteome readily altered by the protein kinase CK2 inhibitor quinalizarin in HEK-293T cells. Biochim Biophys Acta 1854, 609-23
25278378   Curated Info

9

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

10

Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622
25814448   Curated Info

11

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

12

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

13

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

14

Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42
24667141   Curated Info

15

Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76
24117733   Curated Info

16

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

17

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

18

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

19

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

20

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

21

Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37
23628362   Curated Info

22

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info

23

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

24

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

25

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

26

Rikova K (2012) CST Curation Set: 14275; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 2mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

27

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

28

Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876
22673903   Curated Info

29

Osinalde N, et al. (2011) Interleukin-2 signaling pathway analysis by quantitative phosphoproteomics. J Proteomics 75, 177-91
21722762   Curated Info

30

Grosstessner-Hain K, et al. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome. Mol Cell Proteomics 10, M111.008540
21857030   Curated Info

31

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

32

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

33

Herskowitz JH, et al. (2010) Phosphoproteomic Analysis Reveals Site-Specific Changes in GFAP and NDRG2 Phosphorylation in Frontotemporal Lobar Degeneration. J Proteome Res 9, 6368-79
20886841   Curated Info

34

Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97
20815410   Curated Info

35

Zhou J (2010) CST Curation Set: 10708; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

36

Iliuk AB, et al. (2010) In-depth analyses of kinase-dependent tyrosine phosphoproteomes based on metal ion-functionalized soluble nanopolymers. Mol Cell Proteomics 9, 2162-72
20562096   Curated Info

37

Possemato A (2010) CST Curation Set: 10051; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

38

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

39

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

40

Ge F, et al. (2010) Phosphoproteomic analysis of primary human multiple myeloma cells. J Proteomics 73, 1381-90
20230923   Curated Info

41

Han G, et al. (2010) Phosphoproteome analysis of human liver tissue by long-gradient nanoflow LC coupled with multiple stage MS analysis. Electrophoresis 31, 1080-9
20166139   Curated Info

42

Raijmakers R, et al. (2010) Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer. Anal Chem 82, 824-32
20058876   Curated Info

43

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

44

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

45

Højlund K, et al. (2009) In vivo phosphoproteome of human skeletal muscle revealed by phosphopeptide enrichment and HPLC-ESI-MS/MS. J Proteome Res 8, 4954-65
19764811   Curated Info

46

Depontieu FR, et al. (2009) Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy. Proc Natl Acad Sci U S A 106, 12073-8
19581576   Curated Info

47

Nagano K, et al. (2009) Phosphoproteomic analysis of distinct tumor cell lines in response to nocodazole treatment. Proteomics 9, 2861-74
19415658   Curated Info

48

Old WM, et al. (2009) Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell 34, 115-31
19362540   Curated Info

49

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

50

Tsai CF, et al. (2008) Immobilized metal affinity chromatography revisited: pH/acid control toward high selectivity in phosphoproteomics. J Proteome Res 7, 4058-69
18707149   Curated Info

51

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

52

Xia Q, et al. (2008) Phosphoproteomic analysis of human brain by calcium phosphate precipitation and mass spectrometry. J Proteome Res 7, 2845-51
18510355   Curated Info

53

Stokes M (2008) CST Curation Set: 4609; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

54

Stokes M (2008) CST Curation Set: 4393; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

55

Stokes M (2008) CST Curation Set: 4394; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

56

McNulty DE, Annan RS (2008) Hydrophilic interaction chromatography reduces the complexity of the phosphoproteome and improves global phosphopeptide isolation and detection. Mol Cell Proteomics 7, 971-80
18212344   Curated Info

57

Stokes M (2008) CST Curation Set: 3885; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

58

Stokes M (2008) CST Curation Set: 3886; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

59

Imami K, et al. (2008) Automated Phosphoproteome Analysis for Cultured Cancer Cells by Two-Dimensional NanoLC-MS Using a Calcined Titania/C18 Biphasic Column. Anal Sci 24, 161-6
18187866   Curated Info

60

Olsen JV, et al. (2006) Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127, 635-48
17081983   Curated Info